[在代谢功能障碍相关性脂肪性肝炎（MASH）患者中，瑞美替罗 80 毫克或 100 毫克在逆转 MASH 和/或肝活检纤维化方面是否优于安慰剂？］

{"title":"[在代谢功能障碍相关性脂肪性肝炎（MASH）患者中，瑞美替罗 80 毫克或 100 毫克在逆转 MASH 和/或肝活检纤维化方面是否优于安慰剂？］","authors":"L. Lanthier, D. Grbic, Marc-Émile Plourde, M. Cauchon","doi":"10.1016/j.revmed.2024.05.007","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":94122,"journal":{"name":"La Revue de medecine interne","volume":"49 S3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Among patients with metabolic dysfunction associated steatohepatitis (MASH), is resmetirom 80 or 100mg superior to placebo in reversing MASH and/or fibrosis on liver biopsy, and is it safe?]\",\"authors\":\"L. Lanthier, D. Grbic, Marc-Émile Plourde, M. Cauchon\",\"doi\":\"10.1016/j.revmed.2024.05.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":94122,\"journal\":{\"name\":\"La Revue de medecine interne\",\"volume\":\"49 S3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"La Revue de medecine interne\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.1016/j.revmed.2024.05.007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Revue de medecine interne","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1016/j.revmed.2024.05.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}